HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.

AbstractOBJECTIVE:
To evaluate the clinical value of 16α-[18F]fluoroestradiol (18F-FES) PET/CT in assisting the individualized treatment decisions of breast cancer patients.
METHODS:
Thirty-three breast cancer patients, who underwent both 18F-FES and 18F-FDG PET/CT from July 2010 to March 2013 in our center, were enrolled in this preliminary study. All the patients used 18F-FES PET/CT as a diagnostic tool with a clinical dilemma. We used the maximum Standardized Uptake Value (SUVmax) to quantify ER expression and a cutoff value of 1.5 to dichotomize results into ER positive and negative lesions. All patients were clinically followed up at least 6 months.
RESULTS:
In evaluating equivocal lesions on conventional work-up group (n = 4), three lung lesions and another iliac lesion were enrolled. As for three lung lesions, 18F-FES PET/CT showed one lesion with high uptake, which suggested it was an ER positive metastasis. The other two lesions were 18F-FES negative, which meant an ER negative metastasis or secondary primary tumor. Additionally, one iliac lesion was detected by MRI. 18F-FDG uptake was high at the suspected lesion, whereas 18F-FES uptake was absent; In predicting origin of metastasis group (n = 2), two breast cancer patients had secondary primary tumors were collected. They were 18F-FES negative, which showed low possibility of metastasis from breast cancer and they were all confirmed by biopsy. In detecting ER status in metastasis group (n = 27), 18F-FES PET/CT showed increased 18F-FES uptake in all metastatic lesions in 11 patients; absent in all lesions in 13 patients; and the remaining 3 patients had both 18F-FES positive and negative lesions. Totally, on the basis of the 18F-FES PET/CT results, we found changes in the treatment plans in 16 patients (48.5%, 16/33).
CONCLUSIONS:
18F-FES PET/CT could assess the entire tumor volume receptor status; therefore, it may be used to assist the individualized treatment decisions of breast cancer patients.
AuthorsYifei Sun, Zhongyi Yang, Yongping Zhang, Jing Xue, Mingwei Wang, Wei Shi, Beiling Zhu, Silong Hu, Zhifeng Yao, Herong Pan, Yingjian Zhang
JournalPloS one (PLoS One) Vol. 10 Issue 1 Pg. e0116341 ( 2015) ISSN: 1932-6203 [Electronic] United States
PMID25617853 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Fluorine Radioisotopes
  • Receptors, Estrogen
  • Estradiol
  • 16-fluoroestradiol
Topics
  • Adult
  • Aged
  • Breast Neoplasms (genetics, pathology, therapy)
  • Decision Support Systems, Clinical
  • Estradiol (analogs & derivatives, chemistry)
  • Female
  • Fluorine Radioisotopes
  • Humans
  • Image Processing, Computer-Assisted
  • Middle Aged
  • Positron-Emission Tomography (methods)
  • Receptors, Estrogen (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: